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Unraveling gene expression 
profiles in peripheral motor nerve 
from amyotrophic lateral sclerosis 
patients: insights into pathogenesis
Nilo Riva1,*, Ferdinando Clarelli2,*, Teuta Domi1, Federica Cerri1, Francesca Gallia3, 
Amelia Trimarco4, Paola Brambilla2, Christian Lunetta5, Alberto Lazzerini6, Giuseppe Lauria7, 
Carla Taveggia4, Sandro Iannaccone8, Eduardo Nobile-Orazio3, Giancarlo Comi1,9, 
Maurizio D’Antonio10, Filippo Martinelli-Boneschi2,† & Angelo Quattrini1,†
The aim of the present study is to investigate the molecular pathways underlying amyotrophic lateral 
sclerosis (ALS) pathogenesis within the peripheral nervous system. We analyzed gene expression 
changes in human motor nerve diagnostic biopsies obtained from eight ALS patients and seven patients 
affected by motor neuropathy as controls. An integrated transcriptomics and system biology approach 
was employed. We identified alterations in the expression of 815 genes, with 529 up-regulated and 
286 down-regulated in ALS patients. Up-regulated genes clustered around biological process involving 
RNA processing and protein metabolisms. We observed a significant enrichment of up-regulated small 
nucleolar RNA transcripts (p = 2.68*10-11) and genes related to endoplasmic reticulum unfolded 
protein response and chaperone activity. We found a significant down-regulation in ALS of genes 
related to the glutamate metabolism. Interestingly, a network analysis highlighted HDAC2, belonging 
to the histone deacetylase family, as the most interacting node. While so far gene expression studies in 
human ALS have been performed in postmortem tissues, here specimens were obtained from biopsy 
at an early phase of the disease, making these results new in the field of ALS research and therefore 
appealing for gene discovery studies.
Amyotrophic lateral sclerosis (ALS) is the most common and severe form within the group of motor neuron dis-
eases (MND), characterized by degeneration of both upper and lower motor neurons, leading to death two to five 
years after diagnosis1,2. While most ALS cases apparently occur sporadically (sALS), up to 10% have an affected 
relative and are considered familial (fALS) cases. In spite of recent advances in unraveling the genetic etiology of 
ALS3, mechanism/s of disease initiation and progression still remain elusive, even if protein misfolding and aggre-
gation, dysregulation of RNA processing, proteasome impairment, neuro-inflammation, excitotoxicity, cytoskele-
ton and mitochondrial dysfunctions have been proposed4,5. It has been recently demonstrated that motor neuron 
cell death in ALS is profoundly influenced by neighboring non-neuronal cells, including glial cells, thus impli-
cating a non-cell autonomous mechanism in disease pathogenesis5,6. Neurons are extremely polarized cells and 
neuronal cell body size is exceeded by several orders of magnitude by the length of axons, which represent up 
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to 99% of motor neuron volume. The loss of peripheral motor nerve fibers is a major determinant of disability 
in patients with ALS and the peripheral nervous system (PNS) is involved at an early stage in the pathogenetic 
cascade, before symptom onset. In spite of this, possible detrimental factors within or to the PNS have not been 
extensively examined so far. Therefore, studying the PNS, including cells in contact with the full length of periph-
eral axons, such as Schwann cells, endothelial, interstitial and inflammatory cells, and their environment, could 
constitute an important, alternative approach in order to define the non-cell autonomous mechanisms in ALS5.
Most specimens from ALS patients are obtained post-mortem, de facto limiting the possibility of performing 
studies revealing pathogenetic mechanisms underlying the earliest stages of disease. In clinical practice, early 
differential diagnosis between MND and motor neuropathies (MN) is extremely important, as prognosis and 
therapeutic approach are different. However, there are no reliable biomarkers for ALS diagnosis or disease pro-
gression rate. Over the last years, we validated the motor nerve biopsy as a reliable technique for MND diagnosis 
from the earliest stages of disease7. Taking advantage of this unique repository of human nerve biopsies we inves-
tigated the molecular pathways underlying ALS pathogenesis within the PNS, using a transcriptomic and system 
biology approach. Understanding early events in pathogenesis could be highly valuable for diagnosis, treatment 
and development of novel potential biomarkers.
Results
Motor nerve biopsy from ALS and motor neuropathy patients. Patient’s clinical, pathological and 
demographic information are provided in Supplementary Table S1. Mean age at biopsy and sex distribution did 
not differ between groups (mean age: ALS: 57.6 years, SD: 11.2; MN: 57.7 years, SD: 17.9; Females to Males ratio: 
ALS: 1/7; MN. 4/3), while, as expected, disease duration was significantly longer in MN patients compared with 
ALS patients (mean disease duration: ALS: 16.7 months, SD: 10.0; MN: 64.2 months, SD: 48.8; p < 0.05). The 
mean ALS- Functional Rating Scale-revised value was 38.5 (SD: 4.3), while for MN patients the mean Overall 
Disability Sum Score was 2.7 (SD: 1.8). The diagnostic neuropathological features of ALS and MN patients are 
presented in Fig. 1. As reported elsewhere, the morphological aspects of the motor nerves have been shown to 
differ in patients with a definitive diagnosis of MND or MN7. Signs of active axonal degeneration, focal fibers loss 
and low axonal regeneration suggest a pathological diagnosis of MND. Instead, signs of demyelination/remyelina-
tion and a high number of regenerating clusters, indicating axonal regeneration, support a pathological diagnosis 
of MN.
All patients underwent motor nerve biopsy before the institution of specific therapies (Supplementary Table S1).
Figure 1. Representative neuropathological cases. Transverse semi-thin sections of biopsy of motor nerve 
from an ALS case (A and B) and motor neuropathy patient (C and D). In ALS patients, focal decreased density 
of myelinated nerve fibers (A and B: asterisk) is evident in a nerve fascicles. At higher magnification (B), axonal 
degeneration is evident (arrows). (C) Diffuse mild reduction of myelin nerve fibers is present in a representative 
section from patients with definite diagnosis of motor neuropahty. There are clusters of small myelinated 
fibers (D, arrows), indicating axonal regeneration. In addition small onion bulbs (D, arrowheads), indicating 
remyelination, are present. Bar: (A,C) 50 μ m; (B,D) 10 μ m.
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Differential Expression Analysis in ALS patients. Gene expression analysis was performed on 
motor nerves from ALS and MN patients to identify alterations in gene transcription associated with the dis-
ease. Differential expression was assessed on the 27,679 probes that passed the filter criterion (58% of total, see 
Materials and Methods). A Principal Component Analysis (PCA) score plot for the first 3 PCs and a bar plot with 
percentage of explained variance is reported in Supplementary Figure S1, which shows a separation between ALS 
and MN samples along PC1.
Limma method identified a total of 815 DEGs: of these, 529 were up-regulated and 286 down-regulated in 
ALS patients. A heatmap was generated, showing a clear pattern of bi-clustering of up- and down-regulated 
probes across the two compared conditions (Fig. 2). A list of the most strongly up- and down-regulated DEGs 
(False Discovery Rate: FDR < 0.05 and FC > 2.8 or FC < 1/3) in ALS patients is reported in Tables 1 and 2. 
Proline-rich acidic protein 1 (PRAP1) was the top up-regulated gene (FC = 4.57, p-adjusted = 9.05*10-4). PRAP1 
is expressed in epithelial cells and plays a role in cell-cycle control, promoting cell-survival; however, its role in the 
central nervous system and PNS is unknown8. The most down-regulated gene was a member of the family of the 
heat shock protein 90 kDa beta (member 3, pseudogene): HSP90B3P (FC = 0.032, p-adjusted = 8.60*10-4) with 
unknown molecular function up to date9.
We observed in ALS patients a significant enrichment of small nucleolar RNA (snoRNAs) transcripts: 31 
snoRNAs, against an expected number of 7.9 (ratio = 3.89, p = 2.68*10-11; hypergeometric test) were detected in 
the list of 815 DEGs among upregulated genes (Table 3).
Figure 2. Heatmap representing hierarchical clustering of the 15 samples (columns) and genes (rows) 
detected as differentially expressed according to two different thresholds. (A) FDR < 0.01 and FC > 1.5 or 
FC < 0.66; (B) FDR < 0.05 and FC > 3 or FC < 0.33. The expression level of each gene has been standardized 
by subtracting the gene’s mean expression level and dividing by the standard deviation across all samples. This 
scaled expression value is plotted in red-green scale color, with red indicating higher expression and green lower 
expression in ALS patients.
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DEG validation by qRT-PCR and Immunohistochemistry. For a subset of transcripts, quantitative 
real-time RT-PCR and immunohistochemistry were used to corroborate and validate microarray results. Genes 
were selected based on fold changes (> 2) and functions such as genes involved in the development of the nervous 
system (LMNA and TFRC), axon guidance (DPYSL4), RNA processing and small ribosomal subunit assembly 
(NOP14) and mitochondrial functions (MRLP43). The results of quantitative RT-PCR validation, performed on 
three randomly selected samples for each group, demonstrated a positive correlation with the microarray data for 
four of the selected genes, while for MRLP43 the correlation was not significant (Supplementary Tables S2 and S3; 
Supplementary Figures S2 and S3).
To establish the localization and the pattern of expression for PRAP1, LMNA, DPYSL4 and NOP14 in the 
PNS, we performed immunohistochemistry analysis on cross sections of human motor nerves and SOD1G93A 
mice sciatic nerves. We showed a significant correlation between mRNA and protein levels for all selected proteins 
(Figs 3 and 4). PRAP1, LMNA and DPYSL4 displayed elevated signal in the ALS motor nerve (Fig. 3B–D,F–H 
and J–L) compared to the nerve from MN patients (Fig. 3A,E and I). In the current study, expression of PRAP1 
immunoractivity was observed at high level ubiquitously throughout the endoneurium in motor nerves from 
ALS compared to MN nerves. PRAP1 was expressed in the cytoplasm of myelin-forming Schwann cells, iden-
tified by myelin basic protein (MBP), fibroblasts and endothelial cells (Fig. 3B–D). Conversely, both the nuclei 
and cytoplasm of the Schwann cells, other endoneurial and perineurial cells were labed by the LMNA antibody 
(Fig. 3F–H). Similarly to LMNA, in ALS nerves, we observed differences in the expression of DPYSL4 compared 
with MN nerves. DPYSL4 was expressed at high level in the endoneurium and perineurium, both in the nuclei 
and cytoplasm of the Schwann cells, endothelial cells and perineurial cells (Fig. 3J–L). We further investigated 
the expression of NOP14 in the SOD1G93A mice model and control animals. Results showed similar expression of 
NOP14 in the nuclei of the Schwann cells, in both control nerves (Fig. 4A–D) and SOD1G93A at 90 days (disease 
onset) (Fig. 4E–H). SOD1G93A nerves showed increase expression of NOP14 in cell nuclei of the Schwann cells at 
120 days (end-stage disease) (Fig. 4I–L), correlating with disease progression. To the best of our knowledge, this 
is the first demonstration of PRAP1, LMNA, DPYSL4 and NOP14 expression and localization in ALS nerves.
To confirm further the Schwann cells origin of the transcripts, we compared our data on DEGs with a gene 
profiling study on normal and neuropathic mouse nerves10 (see Material and Methods); this analysis suggested 
that most up- or down-regulated genes are expressed in peripheral nerve and thus are likely Schwann cell specific 
(Tables 1 and 2).
Pathway Analysis. DEGs were then classified into functional groups according to Gene Ontology (GO) 
annotation tools. Functional enrichment analysis revealed 16 and one GO terms significantly enriched with DEGs 
in up- and down-regulated genes, respectively. As shown in Table 4A, terms enriched with genes up-regulated 
Gene ID Gene Symbol Name
Chromosomal 
location
Fold-
change P-value
Adjusted 
P-value
Mouse SN 
microarray
Neuropathic Mouse 
SN microarray
ILMN_1815556 PRAP1 proline-rich acidic protein 1 10q26.3f 4,5733 2,52E-006 9,05E-004 N.D. N.D.
ILMN_1792356 DPYSL4 dihydropyrimidinase-like 4 10q26.3e 4,0085 2,01E-005 2,29E-003 Marginal Unchanged
ILMN_1705397 PDK2 pyruvate dehydrogenase kinase, isozyme 2 17q21.33a 3,8222 1,51E-005 2,02E-003 Expressed Unchanged
ILMN_2318568 HCFC1R1 host cell factor C1 regulator 1 (XPO1 dependent), transcript variant 3 16p13.3d 3,5308 1,28E-006 7,38E-004 High-expressed Unchanged
ILMN_1653927 SNORD83A small nucleolar RNA, C/D box 83A, small nucleolar RNA. 22q13.1d 3,3427 1,71E-005 2,15E-003 A. A-
ILMN_1652147 MRPL43 mitochondrial ribosomal protein L43 10q24.31a 3,2241 1,05E-005 1,66E-003 High-expressed Unchanged
ILMN_1661708 LGALS7 lectin, galactoside-binding, soluble, 7 (galectin 7) 19q13.2a 3,2097 8,71E-005 4,38E-003 High-expressed Unchanged
ILMN_1702009 SV2A synaptic vesicle glycoprotein 2A 1q21.2a 3,0984 1,24E-004 5,22E-003 N.D. N.D.
ILMN_1701875 ZYX zyxin, transcript variant 1 7q34f 3,0589 1,19E-004 5,10E-003 High-expressed Unchanged
ILMN_1800843 SCAMP4 secretory carrier membrane protein 4 19p13.3h 3,0321 1,20E-004 5,11E-003 Expressed Unchanged
ILMN_1779177 U2AF1L4 U2 small nuclear RNA auxiliary factor 1-like 4, transcript variant 2 19q13.12a 3,0268 6,16E-005 3,72E-003 Expressed Unchanged
ILMN_3236224 SNORA74A small nucleolar RNA, H/ACA box 74A, small nucleolar RNA 5q31.2d 2,9864 1,27E-005 1,81E-003 A
ILMN_2123450 FLJ43093 FLJ43093 protein 6p21.31a-p21.2c 2,9144 1,09E-004 4,91E-003 A
ILMN_1779875 THY1 Thy-1 cell surface antigen 11q23.3f 2,8812 3,73E-004 9,75E-003 Expressed Unchanged
ILMN_1762294 ADAMTSL4 ADAMTS-like 4, transcript variant 2 1q21.2b-q21.2c 2,8805 3,15E-005 2,65E-003 Expressed Unchanged
ILMN_1666976 PLD3 phospholipase D family, member 3, transcript variant 1 19q13.2b 2,8677 2,21E-006 8,60E-004 Expressed Unchanged
ILMN_1696749 LMNA lamin A/C, transcript variant 2 1q22c 2,8589 1,90E-007 3,22E-004 High-expressed Increased
ILMN_1713247 FSCN2 fascin homolog 2, actin-bundling protein, retinal 17q25.3f 2,8089 1,40E-004 5,61E-003 N.D. N.D.
Table 1.  Differentially expressed genes (DEGs): Up-regulated genes. SN = Sciatic nerve; A. = absent in 
the microarray; N.D. = present in the microarray but not detected; Marginal = very low levels of expression; 
Expressed = present in sciatic nerve, very likely in Schwann cells; High-expressed = abundant in sciatic nerve.
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in ALS patients were ‘response to unfolded protein’ (FDR = 0.008) along with its descendant term ‘endoplasmic 
reticulum unfolded protein response’ (FDR = 0.008) and ‘positive regulation of nuclease activity’ (FDR = 0.03). 
Genes down-regulated in ALS were over-represented in biological processes involving glutamate metabolism: 
‘transferase activity, transferring nitrogenous groups’ (FDR = 0.01). These include CCBL2, also called KAT3 
(Kinurenine Aminotransferase III), which is involved in the synthesis of kynurenic acid (KYNA), an important 
endogenous antagonist of NMDA and alpha 7-nicotinic acetylcholine receptors11.
We further tested over-representation of DEGs in the context of Reactome database12. This analysis revealed 
enrichment of prominent changes in up-regulated genes in four pathways (Table 4B). We consistently retrieved 
genes related to ‘Metabolism of proteins’ (FDR = 0.0082) and the three hierarchically related pathways: ‘Unfolded 
Protein Response (UPR)’ (FDR = 0.0028), ‘Activation of Chaperones by IRE1alpha’ (FDR = 0.0072) and 
‘Activation of Chaperone Genes by XBP1(S)’ (FDR = 0.0072). The IRE1alpha-XBP1 pathway plays relevant roles 
in both physiological and pathological conditions, modulating target genes involved in lipid synthesis, endoplas-
matic reticulum (ER) protein degradation and protein folding13. Notably, among the up-regulated genes anno-
tated in these pathways Lamin A/C (LMNA) is required for normal development of skeletal muscle and PNS; 
moreover, mutations in the LMNA gene are associated with muscular dystrophy and hereditary peripheral neu-
ropathy (Charcot-Marie-Tooth disease)14,15.
Network Analysis. Of the 815 DEGs, 766 were mapped on STRING human interactome database for con-
structing interaction network16. Of these, 266 nodes were interacting with 343 edges distributed over 35 con-
nected components, which were globally enriched in interactions (observed 343; expected: 274; p = 3.5*10-5 
according to STRING null random network model). HDAC2, belonging to the histone deacetylase family, was 
the most interacting node (Fig. 5A). HDAC2 plays an important role in transcriptional regulation and modulates 
relevant neuronal processes such as neuronal differentiation17; furthermore, HDAC1 and HDAC2 are essential for 
Schwann cells survival and myelination by the induction of transcriptional factors for myelin genes18,19.
Cluster analysis on the largest connected component (181 nodes, 287 interactions) highlighted three mod-
ules (Fig. 5B–D): sub-network-1 (n = 12, Q = 0.72, p = 5.7*10-5), sub-network-2 (n = 8, Q = 0.91, p = 3.0*10-4) 
and sub-network-3 (n = 7, Q = 0.72, p = 2*10-3). GO enrichment analysis was performed on member genes 
of these sub-networks. The most specific over-represented terms for the three modules are shown in Table 5: 
sub-network-1 is enriched with genes related to G-protein coupled receptor signalling pathway (FDR = 5.11*10-5); 
ribosomal RNA processing is over-represented in genes belonging to sub-network-2 (FDR = 2.78*10-7) 
Gene ID Gene Symbol Name
Chromosomal 
location
Fold-
change P-value
Adjusted 
P-value
Mouse SN 
microarray
Neuropathic Mouse 
SN microarray
ILMN_1690894 HSP90B3P Heat shock protein 90kDa beta, member 3. 1p22.2 0.0866 8.62E-008 2.94E-004 High-expressed Increased
ILMN_3243441 EEF1AL7 eukaryotic translation elongation factor 1 alpha-like 7. 4q24 0.0958 9.40E-012 2.60E-007 A. —
ILMN_1777976 SLC25A26 solute carrier family 25, member 26. 3p14.1 0.1295 7.54E-006 1.39E-003 Expressed Unchanged
ILMN_2102515 PGAM4 phosphoglycerate mutase family member 4. Xq21.1 0.1765 1.88E-006 8.60E-004 N.D. N.D.
ILMN_1739622 PPP1R12A protein phosphatase 1, regulatory (inhibitor) subunit 12A. 12q21.2-q21.31 0.1921 4.02E-010 5.56E-006 Expressed Unchanged
ILMN_1696035 C12orf8 chromosome 12 open reading frame 8. 12q24.13 0.2117 9.57E-008 2.94E-004 High-expressed Unchanged
ILMN_2213558 TMED10P transmembrane emp24-like trafficking protein 10. 8q24.3 0.2229 1.98E-006 8.60E-004 A. —
ILMN_2294762 AMY1A amylase, alpha 1A, transcript variant 1. 1p21.1 0.2428 1.19E-006 7.01E-004 High-expressed Unchanged
ILMN_1726327 AMY1B amylase, alpha 1B. 1p21.1 0.2705 3.83E-007 3.65E-004 High-expressed Unchanged
ILMN_1695311 HLA-DMA major histocompatibility complex, class II, DM alpha. 6p21.32 0.2872 3.08E-007 3.65E-004 A. —
ILMN_1675331 PEG3 paternally expressed 3. 19q13.43 0.2957 6.91E-007 5.37E-004 High-expressed Unchanged
ILMN_1674243 TFRC transferrin receptor (p90, CD71). 3q29 0.3238 6.76E-007 5.37E-004 Marginal Unchanged
ILMN_2300695 IKZF3 IKAROS family zinc finger 3, transcript variant 1. 17q12 0.3246 1.91E-006 8.60E-004 N.D. N.D.
ILMN_3241051 LOC644907 hCG18290. 7p13d 0,3348 1,13E-006 7,01E-004 A. —
ILMN_2069060 RBM11 RNA binding motif protein 11. 21q11.2c 0,337 6,80E-006 1,35E-003 N.D. N.D.
ILMN_2367239 RCAN1 regulator of calcineurin 1, transcript variant 2. 21q22.12a 0,3494 4,04E-005 2,99E-003 Expressed Unchanged
ILMN_1776515 MPPE1 metallophosphoesterase 1. 18p11.21e 0,3498 1,55E-006 7,96E-004 A. —
ILMN_1670841 CPNE1 copine I, transcript variant 8. 20q11.22b 0,3564 1,58E-006 7,96E-004 Expressed Unchanged
Table 2.  Differentially expressed genes (DEGs): Down-regulated genes. SN = Sciatic nerve; A = absent in 
the microarray; N.D. = present in the microarray but not detected; Marginal = very low levels of expression; 
Expressed = present in sciatic nerve, very likely in Schwann cells; High-expressed = abundant in sciatic nerve.
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and the third module was characterized mainly by genes involved in microtubule cytoskeleton organization 
(FDR = 0.0052).
Regarding active module search, the two modules with the highest score (S1 = 16.13, S2 = 6.8) were selected 
and are displayed in Supplementary Figures S4A and S5A. Module-1 is composed of 338 genes and 1378 edges, 
whereas module-2 involves 189 nodes interacting with 833 edges. Pathway analysis revealed that module-1, 
a sub-network centered on UBC hub gene (degree = 270), was over-represented of genes participating to, 
among others, “protein modification by small protein conjugation” (FDR = 1.05*10-5), “mRNA processing” 
(FDR = 2.4*10-6) and “RNA splicing” (FDR = 5.8*10-6). As regarding module-2 (Supplementary Figure S5A), 
we found that “histone modification” was the most significantly over-represented Biological Process GO term 
among the most specific terms (FDR = 9.5*10-13). This module was enriched of genes involved in “histone meth-
yltransferase activity” (FDR = 8.8*10-5) and in “NAD-dependent histone deacetylase activity” (FDR = 3.6*10-9): 
indeed, again, HDAC2 was the top-interacting node (degree = 50), also exhibiting the higher clustering coefficient 
(c = 0.42) which is a measure of cohesiveness of the node’s first-order neighbors, revealing the important role 
played by this down-regulated gene. Other enriched specific gene-sets were the “negative regulation of transcrip-
tion from RNA polymerase II promoter” (FDR = 9.5*10-9), and the “delayed rectifier potassium channel activity” 
(FDR = 1.1*10-7). The most over-represented specific GO terms are reported in Supplementary Figures S4B and 
S5B.
Discussion
This study was based on previous evidence suggesting that the early events in ALS pathogenesis may be influ-
enced by the PNS cells, such as Schwann cells, and environment, exerting a non-cell autonomous effect on motor 
neuron axons5,6. Our aim was to identify genes, molecular pathways and biomarkers relevant for human ALS. The 
results of our study show, for the first time, specific gene expression changes in motor nerve biopsies of sporadic 
ALS patients as compared with MN patients. We identified both pathways previously reported to be relevant for 
ALS, supporting potential pathogenetic causality4,5, as well as novel potential players in ALS pathogenesis.
Pathways significantly enriched in up-regulated genes include metabolism of protein, UPR, ER stress, acti-
vation of chaperones and positive regulation of nuclease activity. Coherently, GO analysis performed on active 
Probe ID GeneSymbol Chromosomal location Fold-change P-value Adjusted P-value
ILMN_1653927 SNORD83A 22q13.1 3.3427 1.70E-005 0.002147
ILMN_3236224 SNORA74A 5q31.2 2.9864 1.30E-005 0.001812
ILMN_3235154 SNORD124 17q21.1 2.787 4.80E-005 0.003316
ILMN_3244449 SNORD9 14q11.2 2.7101 1.20E-005 0.001734
ILMN_3236408 SCARNA5 2q37.1 2.6914 1.39E-004 0.005604
ILMN_3239932 SNORA53 12q23.1 2.632 5.90E-005 0.003654
ILMN_3238745 SNORA55 1p34.2 2.6075 2.20E-005 0.002408
ILMN_3248232 SNORA2A 12q13.11 2.5964 8.00E-006 0.001429
ILMN_3248394 SNORD63 5q31.2 2.575 1.60E-005 0.002037
ILMN_3245605 SNORA71A 20q11.23 2.5131 2.09E-004 0.007109
ILMN_3241016 SCARNA1 1p35.3 2.4616 1.00E-005 0.001659
ILMN_3238670 SNORA47 5q14.1 2.3529 2.65E-004 0.008049
ILMN_3248811 SNORA27 13q12.2 2.3438 2.90E-004 0.008516
ILMN_3235264 SNORA48 17p13.1d 2.308 7.00E-006 0.001346
ILMN_3247303 SNORD85 1p35.2∞ 2.1807 1.10E-004 0.004911
ILMN_3246869 SCARNA21 17p13.1 2.1485 1.50E-005 0.002021
ILMN_3239574 SNORD3A 17p11.2 2.0318 8.00E-005 0.004301
ILMN_3243908 SNORA43 9q34.3 2.0222 8.50E-005 0.004352
ILMN_3239162 SNORA31 13q14.12 1.9989 4.00E-005 0.00299
ILMN_2085525 SNORA32 11q21 1.986 3.10E-005 0.002646
ILMN_3245672 SNORD84 6p21.33 1.9767 3.69E-004 0.009719
ILMN_3249538 SNORA2B 12q13.11 1.9743 9.80E-005 0.004666
ILMN_3240781 SNORD17 20p11.23 1.9585 9.70E-005 0.004624
ILMN_3242825 SNORA50 16q21 1.9111 2.96E-004 0.008589
ILMN_3241139 SNORD57 20p13 1.863 7.00E-006 0.001389
ILMN_3240150 SNORA75 2q37.1 1.8398 2.10E-005 0.00229
ILMN_3248874 SNORD8 14q11.2 1.8007 2.63E-004 0.008012
ILMN_3242448 SNORA11D Xp11.22 1.7561 1.82E-004 0.006503
ILMN_1689616 SNORA66 1p22.1 1.714 1.30E-005 0.001853
ILMN_3243921 SNORA11E Xp11.22 1.7047 1.52E-004 0.00584
ILMN_3237044 SNORD36B 9q34.2 1.6336 3.04E-004 0.008681
Table 3.  Small Nucleolar RNA (SNORNAs) enriched in DEGs.
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subnetwork module-1 showed a significant over-representation of pathways related to ubiquitin-protein ligase 
activity, SUMO ligase activity and Ubiquitin C was the most relevant hub gene.
Impaired protein degradation is a well-recognized potential causative effect in ALS pathogenesis, supported 
by the discovery of fALS-linked mutations affecting proteins that are directly involved in proteostasis such as 
SOD1, which account for about 20% of fALS, but also ubiquitin 2 (UBQLN2) and Optineurin (OPTN)3. Mutant 
SOD1 misfolds, accumulates as oligomers in the ER and later as aggregates, leading in turn to activation of UPR20. 
Indeed the UPR aim is to restore proper folding by stalling protein translation; however, when unsuccessful, 
it determines apoptosis21. Accordingly, in ALS patients we found up-regulation of genes related to activation 
of chaperones by the IRE1/XBP1 pathway, one of the most important stress sensors controlling the UPR13. 
Interestingly, the UPR can be modulated by guanabez, a drug approved for the treatment of hypertension, which 
shown a potential neuroprotective effect in the SOD1G93A mouse model of ALS22.
Figure 3. Immunohistochemistry localization of PRAP1, LMNA and DPYSL4 in MN and ALS motor 
nerves. Double staining for MBP (red), to mark myelinated nerve fibers, and PRAP1 (A–D), LMNA ( E–H) 
and DPYSL4 (I–L) (brown) shows increase expression in ALS motor nerves. PRAP1 immunoreactivity was 
present in the endoneurium in numeorus cells (arrowheads, B,C) including cytoplasm of Schwann cells 
(arrows, B; MBP immunoreactivity identified the myelin sheath) and endothelial cells (arrow, D). LMNA shows 
immunoreactivity in the perineurium in both MN and ALS nerves (arrowhead, E,F); in ALS motor nerves, 
immunoreactivity was present in nuclei and cytoplasm of all endoneurial cells (arrowhead, G,H) and Schwann 
cells (arrows, F–H). In ALS motor nerves, DPYSL4 was expressed in perineurium (arrowhead, J) and in the 
cytoplams and nuclei of many cells (arrows in J–L) including endothelial cells (arrowhead, K) and Schwann 
cells (arrows J,K). Bar: (A,E,I) 50 μ m; (F–H,J–L) 50 μ m.
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No previous study has studied gene expression profiles in motor nerves of ALS patients at disease onset, there-
fore, no direct comparison is possible. However, a recent systematic meta-analysis has highlighted genes that were 
found to be differentially expressed at least two times: between the DEGs identified, six are also shared with our 
study, namely calcium binding protein 1 (CABP1), cathepsin B (CTSB), granulin (GRN), calreticulin (CALR), 
Rh-Associated Glycoprotein (RHAG) and proteolipid Protein 1 (PLP1)23. Of these, CTSB and GRN were repli-
cated in more than one mouse study and in at least one human study24–27. CTSB belong to a family of lysosomal 
proteases26,27 while GRN, similarly, is another gene involved in protein turnover whose mutations are associated 
with frontotemporal lobar degeneration with ubiquitin-positive inclusions28.
Interestingly, CALR is not only a key protein in the maintenance of Ca2+ levels inside the ER, but is also a 
chaperone protein, regulating the folding of newly synthesized proteins29. Moreover, we found five DEGs over-
lapping between our study and a gene expression study, even though it was performed in late-stage human ALS 
post-mortem spinal cord: PLP1, Protein kinase C zeta (PRKCZ), Cathepsin B (CTSB), Ankyrin G (ANK3) and 
Islet-1 (ISL1)26. Notably, PLP1 encodes for the major myelin proteolipid protein, that plays a role not only for 
stabilization and maintenance of myelin sheaths, but also for axonal survival; mutations in this gene cause spastic 
paraplegia type 2 and Pelizaeus-Merzbacher disease30. Interestingly, ANKG is a key component of the nodes of 
Ranvier and mutations in ANK3 are associated with psychiatric disorders including schizophrenia, autism and 
bipolar disorder31.
In ALS motor nerve, we also observed the differential expression of many genes and pathways related to 
RNA processing. ALS patients showed increased expression of snoRNAs, a large family of small non-coding 
Figure 4. Expression of NOP14 in the sciatic nerve of normal and SOD1G93A mice. Tranverse sections from 
wild-type (A–D), SOD1G93A mice at 90 days (diseases onset) (E–H) and 120 (end-stage disease) (I–L) double-
stained for neurofilament (green), to recognize axons, and NOP14 (red). DAPI staining of nuclei (blue). Nop14 
immunoreactivity was present in cell nuclei in wild-type nerves (arrowhead, merge in D); NOP14 shows an 
increase expression in SOD1G93A nerves in cell nuclei of the Schwann cells (arrowhead, merge in H and L); 
perineurial cells were also positive for NOP14 (merge in H and L, arrows). Bar: (A–L) 120 μ m.
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RNAs (ncRNAs) which represent a class of regulatory RNAs responsible for post-transcriptional maturation of 
ribosomal RNAs (rRNAs). SnoRNAs guide modification of rRNA and snRNA nucleotides, influence alternative 
splicing of complementary pre-mRNAs, and control translation and stability of mRNAs through RISC-dependent 
activity. Thus, we cannot exclude a direct role of snoRNAs in ALS pathogenesis, considering the growing evidence 
for a role of snoRNA and other ncRNAs in neurological diseases32. Moreover, recent studies have independently 
demonstrated several non-canonical functions for snoRNAs, including miRNA-like capabilities. In turn, miRNAs 
dysregulation may play a critical role in neurological disorders pathogenesis, including ALS33. In agreement, two 
genes with a recognized role in RNA metabolism and miRNAs biogenesis, namely TAR DNA-binding protein-43 
(TDP43) and fused in sarcoma/translocated in liposarcoma (FUS/TLS), are mutated in fALS cases34. Finally, four 
hub genes in network analysis were related to ribosomes (RPL10A and RPL21) and RNA metabolism (EIF4A1 
and U2AF2) and in identified sub-networks we observed a significant enrichment of ncRNA processing and 
ribosome biogenesis, confirming the relevance of these biological processes in ALS. Moreover, in keeping with 
these results, GO analysis performed on active subnetwork module-1 showed a significant over representation of 
pathways related to mRNA processing and splicing.
Pathway analysis showed in ALS patients major down-regulations in genes related to glutamate metabolism, 
such as CCBL2, also called KAT3 (Kynurenine aminotransferase), supporting the role of glutamate-induced exci-
totoxicity in ALS pathogenesis, coherently with previous reports35. KAT3 catalyzes the synthesis of kynurenic 
acid (KYNA), a known endogenous antagonist of the NMDA (n-methil-D-aspartate) glutamate receptors. KYNA 
is believed to play a role in modulating glutamate-mediated neurotransmission11. Abnormal concentrations of 
KYNA in brain tissue has been linked to a number of human neurodegenerative diseases12,36. The kynurenine 
pathway has recently emerged as a potential contributing factor in ALS pathogensesis, and could offer novel 
therapeutic target option for ALS36.
Neuro-inflammation and dysregulated expression of cytoskeleton related genes have been implicated in 
ALS37,38. In ALS motor nerves, our analysis did not reveal any significant over-representation of inflammatory 
pathways, indirectly supporting the hypothesis that inflammation could be secondary to nerve fibers damage and 
hence induced in both diseases39. However, CCR2 was down-regulated in ALS. CCR2 and its ligand monocyte 
chemoattractant protein-1 (MCP-1) play a role in the macrophage inflammatory response following PNS injury, 
and promote nerve regeneration40. CCR2 and MCP-1 have previously been reported to be implicated in both 
ALS41 and peripheral neuropathies pathogenetic cascade42. Our finding corroborates the hypothesis that defective 
monocyte/macrophages infiltration at the site of nerve degeneration may be implicated in ALS. Instead, the net-
work analysis recognized genes belonging to the microtubule cytoskeleton organization, suggesting impairment 
in axonal transport, in agreement with a previous study analyzing the sciatic nerve of the SOD1G93A transgenic 
mice38. Nonetheless, we cannot exclude the possibility that cytoskeleton-related genes dysregulation might reflect 
a response to injury process rather than having a specific role in disease pathogenesis and neurodegenerative 
triggering.
Term ID Statistics a Annotated DEGs
A Enriched Gene Ontology Terms
Terms enriched with 
up-regulated genes
Response to unfolded 
protein GO:0006986
C = 127; O = 13; E = 3.21; R = 4.05; 
rawP = 1.96e-05; adjP = 0.0080
SRPRB, CCND1, CALR, CUL7, HSPA4, TLN1, TSPYL2, 
ERO1L, BAX, CREB3L1, HSPA7, LMNA, PREB
Endoplasmic 
reticulum unfolded 
protein response 
GO:0030968 C = 83; O = 10; E = 2.10; R = 4.76; rawP = 4.44e-05; adjP = 0.0121
SRPRB, CCND1, CALR, CUL7, TLN1, TSPYL2, ERO1L, 
BAX, LMNA, PREB
Positive regulation of 
nuclease activity GO:0032075
C = 65; O = 8; E = 1.64; R = 4.86; 
rawP = 0.0002; adjP = 0.0306
SRPRB, CALR, HMGB2, CUL7, TLN1, TSPYL2, LMNA, 
PREB
Terms enriched with 
down-regulated genes
Transferase activity, 
transferring 
nitrogenous groups 
GO:0016769 C = 22; O = 4; E = 0.27; R = 14.71; rawP = 0.0001; adjP = 0.0141 CCBL2, AGXT2L2, ABAT, GATM
B Enriched Reactome pathways
Pathways ID Statistics b Annotated DEGs
Pathways enriched with 
up-regulated genes
Unfolded Protein 
Response 381119
Gene Ratio = 8/143; 
BgRatio = 65/6196; pvalue = 1.09E-
004; adjP = 2.85E-003
LMNA, PREB, ATF4P3, CUL7, SRPRB, TSPYL2, TLN1, 
CALR
Activation of 
Chaperone Genes by 
XBP1(S)
381038
Gene Ratio = 6/143; 
BgRatio = 46/6196; pvalue = 5.95E-
004; adjP = 7.28E-003
LMNA, PREB, CUL7, SRPRB, TSPYL2, TLN1
Activation of 
Chaperones by 
IRE1alpha
381070
Gene Ratio = 6/143; 
BgRatio = 49/6196; 
pvalue = 8.40E-004;adjP = 7.28E-003
LMNA, PREB, CUL7, SRPRB, TSPYL2, TLN1
Metabolism of 
proteins 392499
Gene Ratio = 25/143; 
BgRatio = 573/6196; pvalue = 1.26E-
003; adjP = 8.21E-003
LMNA, PREB, ATF4P3, FBXW9, PIGQ, EIF5B, PRKCSH, 
TOMM40, CUL7, SRPRB, EIF5A, RPL10A, TSPYL2, 
USP11, TUBB2A, SLC30A5, TLN1, ARSD, PIGW, INS-
IGF2, CALR, IDH3G, ERO1L, F7, SPCS2
Table 4.  Pathway analysis. a and b: Statistics according to WebGestalt. C: n. of genes belonging to the 
term in GO database; O: n. of observed genes; E: n. of expected genes; R: ratio O/E; rawP: raw p-value for 
hypergeometric test in WebGestalt; adjP: p-value for hypergeometric test adjusted for Benjamini-Hochberg 
correction. GeneRatio: ratio between the number of DEGs in the pathway and the number of DEGs. BgRatio: 
ratio between the number of genes in the pathway and the total examined background of genes.
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Notably, network analysis of DEGs highlighted HDAC2, belonging to the histone deacetylases family, as 
the most interacting node, which was coherently also the top-interacting node of active subnetwork module-2, 
showing a significant over-representation of pathways related to histone-deacetilase, histone methyltransferase 
activities, the nucleosome remodeling and deacetylase complex (NuRD). HDAC2 plays an important role in 
transcriptional regulation and modulates relevant neuronal processes such as neural differentiation and axonal 
regeneration17, opening new potential windows of pharmacological interventions in neurodegenerative disease. 
Furthermore, HDAC1 and HDAC2 are essential for Schwann cells survival and myelination due to the induction 
of transcriptional factors for myelin genes18,19. In the context of ALS, transcriptional dysregulation is recently 
an emerging factor in the progression of the disease43. It has been proposed that HDAC6 regulates aggresome 
Figure 5. Interaction networks among differentially expressed genes as retrieved from STRING database 
at confidence score >0.7. (A) Largest connected network, with subnetwork modules mined by ClusterONE 
algorithm as densely connected regions, highlighted in (B–D). Nodes are color-coded according to values of 
log2 (fold-change), with red and green nodes representing up-regulated and down-regulated genes respectively, 
and color saturation prorportional to level of modulation. Node size is proportional to degree connectivity and 
border thickness is proportional to adjusted p-value of association.
Term ID Statistics Annotated DEGs
SUBNETWORK-1
adenylate cyclase-inhibiting 
G-protein coupled receptor 
signaling pathway (BP)
GO:0007193  C = 41; O = 3; E = 0.03; R = 89.01; rawP = 4.33e-06; adjP = 5.11e-05
ADCY3, OPRL1, 
ADORA1
negative regulation of 
transmission of nerve impulse 
(BP) 
GO:0051970  C = 37; O = 3; E = 0.03; R = 98.63; rawP = 3.16e-06; adjP = 5.11e-05 HCRT, AVP, ADORA1
G-protein coupled peptide 
receptor activity (MF) GO:0008528
 C = 101; O = 3; E = 0.08; R = 37.48; 
rawP = 5.91e-05; adjP = 0.0002 CXCR5, OPRL1, CCR2
SUBNETWORK-2
rRNA processing (BP) GO:0006364  C = 101; O = 4; E = 0.04; R = 105.99; rawP = 1.52e-08; adjP = 2.78e-07
UTP23, NOP14, RRP8, 
NOP56
nucleolus (CC) GO:0005730  C = 1479; O = 6; E = 0.67; R = 8.89; rawP = 5.12e-06; adjP = 0.0001
UTP23, NOP14, RRP8, 
DDX52, NAT10, 
NOP56
SUBNETWORK-3
microtubule cytoskeleton 
organization (BP) GO:0000226
 C = 263; O = 3; E = 0.12; R = 25.44; 
rawP = 0.0001; adjP = 0.0052
KIF2A, CLASP2, 
TUBGCP2
microtubule organizing center 
(CC) GO:0005815
 C = 462; O = 4; E = 0.18; R = 22.13; 
rawP = 1.16e-05; adjP = 0.0002
KIF2A, ARL6, CLASP2, 
TUBGCP2
purine ribonucleotide binding 
(MF) GO:0032555
 C = 1750; O = 3; E = 0.76; R = 3.97; 
rawP = 0.0298; adjP = 0.0684 KIF2A, SRPRB, ALR6
Table 5.  Over-represented Gene Ontology Terms in detected subnetworks. Statistics according to 
WebGestalt. C: n. of genes belonging to the term in GO database; O: n. of observed genes; E: n. of expected 
genes; R: ratio O/E; rawP: raw p-value for hypergeometric test in WebGestalt; adjP: p-value for hypergeometric 
test adjusted for Benjamini-Hochberg correction. BP: Biological Process, MF: Molecular Function, CC Cellular 
Component.
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formation of misfolded proteins in mutant SOD144. Furthermore, the inhibition of HDACs with trichostatin A 
reduces axonal degeneration and increases lifespan of ALS mice45, although it remains almost unknown the con-
tribution of HDACs to motor neuron survival and functioning in ALS.
Previous studies have shown that neighboring glial cells exerting a non-cell autonomous effect on motor 
neurons have a crucial role in ALS pathogenesis5,6. Although microglia and astrocytes have been recognized as 
important factors in ALS5, the role of other glial cells, such as Schwann cells, has not been thoroughly investigated 
so far. Recent studies show conflicting results on Schwann cells involvement in the ALS progression. Increase 
expression of SOD1G93A exclusively in Schwann cells of the transgenic mice showed a beneficial effect on disease46. 
While elimination of mutant SOD1G37R determined a worsening in disease progression, suggesting an unexpected 
neuroprotective role for the mutant SOD1 Schwann cells47. Nevertheless, excision of SOD1 in Schwann cells of 
SODG85R mice delayed disease onset and increase survival48. We acknowledge that we extracted the total RNA 
from motor nerve samples which is an heterogeneous tissue, containing the axons of motor neurons and their 
ensheathing Schwann cells, perineurial cells, fibroblasts and endothelial cells; therefore, it is not possible to state 
which cells within the nerve are expressing each individual DEG. However, selected DEGs were expressed pre-
sumably by Schwann cells as showed by immunohistochemistry and gene profiling studies on normal and neu-
ropathic mouse nerves10, where more than 90% of the mRNA is of Schwann cell origin. Taken together, our data 
suggest that PNS environment and possibly Schwann cells might exert a role in the non-cell autonomous ALS 
motor neuron degeneration49, potentially pertaining either ALS causality or progression. Indeed, variants in two 
of our DEGS, a Zinc Finger Protein 512B (ZNF512B) and PGN have been previously reported as either prognostic 
factor or associated to susceptibility to ALS50–52.
Our study is unique as it investigates PNS and its relevance for human ALS by taking advantage of human 
diagnostic motor nerve biopsy samples from early stage of the disease. It is a common dilemma for gene expres-
sion studies the inference of causality: transcriptomic changes may be a consequence of ALS, rather than its 
cause53. Nonetheless, many of the pathways highlighted by our experiments turned out to be involved in ALS, 
supporting potential pathogenetic causality. Moreover, while we acknowledge that one potential limitation of our 
study may be the lack of normal control motor nerves, by comparing two groups of patients with similar diseases 
involving the PNS may also have limited the possibility of highlighting conserved, unspecific response-to-injury 
process. Remarkably, genes chosen for immunohistochemistry validation studies gave results consistent with the 
microarray data showing for the first time the cellular expression of our selected DEGs in motor nerves. To our 
knowledge, this is the first study to identify in vivo the expression and cellular localization in the human motor 
nerve of PRAP1, DPYSL4 and LMNA associated with ALS. Further studies are required to determine the func-
tional significance of these molecules in the progression of ALS.
In conclusion, we define early molecular pathways within the PNS relevant for human ALS. Since extensive 
damage in ALS already occurs by the time clinical symptoms appear, the ability to perform an early diagnosis 
and therapeutic intervention, ideally at the pre-symptomatic stage, could have a more beneficial neuroprotective 
effect on disease. We do not know if our results would be useful in a clinical setting, especially since motor nerve 
biopsies are rarely performed; however the relevance of candidate genes reported in the present study may be a 
source of clinical biomarkers for ALS.
Materials and Methods
Human motor nerves. We analyzed gene expression changes in human obturator motor nerve diagnostic 
biopsies obtained from eight sALS patients at disease onset and from seven patients affected by MN, which were 
used as controls. Normal control motor nerves were not available for this study because we followed the strict 
indication criteria for considering the motor nerve biopsy (Supplementary Table S1). Thus, we have decided to 
performed comparative studies using motor nerve biopsies from two groups of patients to discover transcrip-
tomic changes that could account for the differences in their clinical course.
In ALS patient, following clinic-pathologic diagnosis, mutations in TARDBP, FUS and SOD1 genes as well 
presence of GGGGCC hexanucleotide repeat expansion in the first intron of C9Orf72 were excluded. The 
presence of the GGGGCC hexanucleotide expansion in the first intron of C9orf72 status was assessed using a 
repeat-primed PCR assay54 on an automated ABI3730 DNA-analyzer. A amplicon-length PCR was performed 
to define the length of normal alleles (up to 30 repeats) and to exclude a pathological repeat expansion when two 
normal alleles are detected. In addition, the presence of the GGGGCC expansion was confirmed on a second 
DNA extraction and applying a different repeat-primed PCR protocol55. A cut-off of ≥ 30 repeats combined with a 
typical sawtooth pattern was considered pathological. All the coding exons and 50 bp of the flanking intron-exon 
boundaries of SOD1, of TARDBP and of FUS have been PCR amplified and a direct sequence analysis was per-
formed using the Big-Dye Terminator v1.1 sequencing kit (Applied Biosystems Inc.), and run on an ABIPrism 
3730 genetic analyzer.
All human nerve biopsies had been obtained for diagnostic purposes, after informed consent, and stored in 
our tissue bank, all experimental protocol were approved by San Raffaele Scientific Institute Ethical Committee 
(Milan, Italy), and the methods were carried out in accordance with the approved guidelines. The diagnostic 
biopsy of the anterior branch of the obturator nerve was performed under local anesthesia plus short sedation, 
as described. Briefly, each nerve was divided into three segments. One segment was fixed in 10% formaline for 
routine histology using paraffin embedded tissue. A second segment was fixed in 2% buffered gluteraldehyde and 
post-fixed in 1% osmium tetroxid. After alcohol dehydration, these samples were embedded in Epon. Transverse 
sections (0,5–1 μμ) were stained with toluidine blue and examined by light microscopy. Ultrathin sections were 
stained with uranil-acetate and lead citrate and examined by electron microscope. The third nerve segment was 
frozen and stored in liquid nitrogen, and used for gene expression studies7.
We selected patients meeting the criteria for a pathological diagnosis of probable MND and probable or defi-
nite neuropathy, according to previously published criteria7. ALS clinical diagnosis was further confirmed at 
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follow-up according to El Escorial diagnostic criteria56, while the diagnosis of neuropathy was confirmed accord-
ing to standard criteria. Disability of MN patients was measured using the Overall Disability Sum Score57. For 
ALS patients, disease severity was assessed using the ALS Functional Rating Scale56.
RNA extraction and gene expression analysis. Total RNA was isolated from motor nerve samples 
using the RNeasy kit (Qiagen, Venlo, Netherlands). RNA was quantified using the Nanodrop-2000 spectropho-
tometer (Celbio, Milan, Italy) and Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA) was used to 
assess RNA integrity. Gene expression study was performed using the IlluminaҐ HumanHT-12 v4 BeadChips 
(Illumina Inc., San Diego, California, USA), each individual array targeting more than 47,000 transcripts 
selected primarily from the NCBI RefSeq database (Release 38). We adopted the Illumina Whole-Genome Gene 
Expression DASLҐ HT Assay, which is optimized for degraded RNA58. An amount of 250 ng of total RNA was 
retrotranscribed to cDNA using biotinylated oligo (dT) and random nonamer primers. The biotinylated cDNA 
was then annealed to the DASL Assay Pool (DAP) probe groups, containing specific oligonucleotides of 50 bases 
designed to interrogate each target sequence in the transcripts. Then, universal PCR amplification and Cy3 stain-
ing steps were performed. Finally, the resulting labeled PCR products were hybridized to the BeadChips, which 
were imaged using the IlluminaҐ BeadArray Reader. The software IlluminaҐ GenomeStudio version 2011.1 was 
used to generate fluorescent hybridization signals.
Pre-processing and differential expression. Quality controls and subsequent preprocessing steps were 
performed using R statistical environment59 and Bioconductor package lumi60. We assessed the presence of out-
liers by means of principal component analysis (PCA) and signal intensities distribution analysis with R package 
Array Quality Metrics functions61. Normalization of signals was performed with quantile procedure as available 
in lumi package. Subsequently, probes whose fluorescence signal was deemed close to estimated background were 
excluded: we retained probes that were called ‘present’ by GenomeStudio algorithm (detection call p-value < 0.05) 
on at least 30% of samples in at least one of the two groups62. We performed PCA on the normalized filtered set 
of 27,679 probes. The 15 samples were projected on the first 3 PCs, which overall explain more than 50% of the 
variance of expression.
Differential expression analysis on normalized and filtered dataset was performed using limma method63, 
which relies on a linear model and pooled estimate of gene variance to detect DEGs. Correction for multiple 
testing was done by controlling the False Discovery rate (FDR) with Benjamini-Hochberg procedure64. Threshold 
values to declare DEGs were set to FDR < 0.01 and fold-change (FC) > 1.5 or fold-change < 0.66.
Pathway analysis. Functional enrichment analysis of up- and down-regulated DEGs was performed on 
Gene Ontology and Reactome databases, using WebGestalt65 and Bioconductor R package ReactomePA12. 
Over-representation for both databases was evaluated via hypergeometric test with Benjamini-Hochberg mul-
tiple testing adjustment64, using the filtered set of genes as customized background set. For Gene Ontology, we 
considered for the analysis only terms with at least 3 annotated genes.
Network analysis. The identified DEGs were superimposed on their corresponding proteins available on 
interactome database STRING v10 (Search Tool for the Retrieval of INteracting Genes)16 and a functional and 
protein-protein interaction network, based on experiments, co-expression, literature-mining and databases, was 
retrieved, retaining only high confidence interactions (score > 0.7). The retrieved networks were exported, visu-
alized and analyzed using Cytoscape 3.0, followed by an assessment of centrality metrics (degree and betweeness) 
to reveal possible key-players within the set of DEGs.
Cluster analysis according to network connectivity was carried out with ClusterONE plugin66 in order to 
detect densely connected sub-networks, which are more likely to be considered as functional modules. We 
retained only clusters with at least 6 members and a quality score Q > 0.7 as a measure of cohesiveness. To assess 
biological relevance of mined modules, over-representation of Gene Ontology terms in subnetworks genes was 
evaluated with WebGestalt tool.
We next performed an “active sub-networks” extraction from global human interactome, which we down-
loaded from STRING v10 database, filtering interactions with confidence score> 0.7. The network was imported 
in Cytoscape, mapping the filtered genes onto it and discarding all nodes not present in our set of filtered genes. 
The final analyzed network consisted of 268,759 edges involving 13,714 genes-nodes. We used jActiveModules 
plugin67 to identify active modules, i.e. sub-networks enriched of significantly DEGs and hence reflecting how 
they are “active” under the examined contrast. For each sub-network, jActiveModules computes an aggregate 
score with a size-adjusted sum of z-scores and employs simulated annealing as a search strategy for top-scoring 
modules across the interactome. The overlap threshold between modules was set to 0.2 and the search depth to 1. 
To assess biological meaning, we carried out functional enrichment analysis with WebGestalt using filtered genes 
as background.
Array data validation by Real-Time PCR (qRT-PCR) and Immunohistochemistry. In order 
to validate the microarray results, expression levels of selected DEGs was confirmed by quantitative RT-PCR 
performed on five independent cDNA samples (randomly selected from the pool of patients, three from each 
group, ALS and MN). Transcripts were selected for validation based on having a large change in expression level 
(> 2 fold) the absence of transcript variants and functions. We selected genes involved in development of the 
nervous system (LMNA and TFRC), in axon guidance (DPYSL4), RNA processing and small ribosomal subu-
nit assembly (NOP14) and mitochondrial functions (MRLP43). GAPDH was used for normalization of target 
genes expression. We synthesized cDNA using 200 ng of RNA and performed reverse transcription reaction with 
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AMV Reverse Transcriptase, Oligo (dT)15 Primer and recombinant RNasin Ribonuclease Inhibitor kits (all by 
Promega Corporation, Wisconsin, USA). RT-PCR was performed using Sso Fast EvaGreen Supermix (Bio-Rad 
Laboratories, California, USA) according to manufacturer’s instructions. We used a cDNA amount correspond-
ing to a starting RNA concentration of 5,71 ng for DCTN and TFRC for each reaction and 0,57 ng (1:10) for the 
others. The final concentration of each primer per reaction was 5 uM. Three technical replicates were prepared for 
each sample. PCR were run on the C1000 Thermal Cycler with CFX96 Real-Time System (Bio-Rad Laboratories, 
California, USA). PCR cycling conditions were: enzyme activation 30 sec at 95C, denaturation 5 sec at 95C, 
annealing 5 sec at 56C and extension 20 sec at 60C (40 cycles). Results were analyzed by CFX Manager software 
(Bio-Rad Laboratories, California, USA) and relative expressions were calculated with DDCt method. For each 
gene, the Pearson correlation coefficient was calculated between the log2-transformed expression values as meas-
ured by microarray and the negative of the Ct obtained by RT-qPCR analysis.
To verify the protein levels of the selected genes, immunohistochemical analysis were performed in the patient 
motor nerves and SOD1G93A mice model. Transgenic SOD1G93A and WT mice were purchased from Charles 
Rivers Laboratories Internetional, Inc. (Calco, Italy), maintained and bred at the animal house IRCCS San 
Raffele. Male mice were analyzed at different post-natal days: 90 (disease onset) and 120 days (end-stage disease). 
Animals were sacrified by exposure to carbon dioxide. All procedures were approved by the Animal Experimental 
Committee of the San Raffaele Scientific Institute, Milan, Italy. Procedures were carried out in accordance with 
the IRCCS San Raffaele of Milan Animal Care and Use Guidelines.
NOP14, PRAP1, DYSPL4 and LMNA were selected because their antibodies (Ab) were available. First, all 
Abs were tested to find the optimal staining conditions. For the current study the best staining conditions were: 
polyclonal Ab to PRAP1 (Sigma, dilution 1:250), polyclonal Ab to DPYSL4 (Sigma, dilution 1:100) and polyclonal 
Ab to LMNA (Sigma, dilution 1:100) on paraffin embedded human nerves by immunohistochemestry; instead 
ployclonal Ab to NOP14 (Sigma, dilution 1:500) worked well on mouse cryosections using immunofluorescence 
staining. Double staining was performed with antibodies recognizing the following antigens: Ab anti Myelin Basic 
Protein (MBP) to recognize myelinated nerve fibers and Ab anti Neurofilament (NF) to mark axons.
The immunohistochemistry procedure was performed with NovoCastra Polymer Detection System and 
Ultravision LP detection system (Thermo Scientific) on paraffin sections from patients with ALS and MN used 
in the present study. Sections were de-paraffinize in xylene for 20–30 minuts, then rehydrated through graded 
alcohols. Slides were washed in running tap water for 10 minutes. Endogenous peroxidise were neutralized using 
Peroxidase Block for 5 minutes; subsequently slides were incubated with Protein Block for 5 minutes, washed in 
TBS for 2 × 5 minutes and incubated with primary antibody all night long at room temperature. Double staining 
was performed by consecutively applying on the same section antibodies raised in different species. Next day 
sections were washed in TBS for 2 × 5 minutes and then incubated with Post Primary Block for 30 minutes; after 
this passage NovoLink Polymer was added for 30 minutes. Peroxidase activity with DAB working solution was 
developed for 5 minutes. Slides were rinsed in water and counterstained with hematoxylin. Sections were then 
dehydrated, and mounted with Micromount Mounting Medium.
Double immunofluorescence on SOD1G93A nerves was performed using Ab NOP14 and Ab NF. Sections were 
permeabilized for 2 min with acetone. Sections were incubated at 4C overnight with primary antibody, washed 
twice with PBS for 10 min, and incubated for 30 min with FITC-conjugated or TRITC-conjugated secondary 
antibodies, diluted 1:150 in PBS. Controls included omission of primary antibodies on parallel sections. For nerve 
analysis, digitalized images of fiber cross sections were obtained from sural nerve with a digital camera (Leica 
DFC300F) using a 40X objective of light or fluorescence microscope (Olympus BX51). All slides were interpreted 
by experienced neuropathologists (F.C. and A.Q.); at the time of examination, the pathologists were blinded to all 
clinical and pathological data.
To further establish the Schwann cells origin of the mRNA, the presence/absence of the up- and 
down-regulated DEG in normal and disease peripheral nerve was also assessed by comparing our data with pre-
vious gene profiling studies on wild-type and neuropathic mouse nerves (GEO accession number GSEE40610)10.
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